Synta Pharma (SNTA) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Synta Reports First Quarter 2015 Financial Results
May 7, 2015 7:00 AM EDT- Webcast and Conference Call Today, May 7, at 10:00 AM ET -
LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the first quarter ended March 31, 2015 and provided an operational update.
We remain encouraged by the progress of our ganetespib clinical program including enrollment in our pivotal, Phase 3 GALAXY-2 trial in non-small cell lung adenocarcinoma, and the broad investigator-led trial effort, which includes large, ongoing randomized trials in acute myeloid leukemia and ovarian and breast cancers, said Chen Schor, President and Chief... More
